For best experience please turn on javascript and use a modern browser!
Bekijk de site in het Nederlands

Caroline Drukker evaluates the outcome prediction and clinical relevance of the 70-gene signature for locoregional and distant recurrence, its influence on risk assessment and adjuvant systemic therapy (AST) recommendations, and its additional value to established clinical guidelines used in breast cancer treatment. In addition, Drukker uses the 70-gene signature to gain better insight in the biological background of tumors detected in a population-based screening programme.

Event details of Gene signature for treatment of breast cancer
Date 28 March 2014
Time 12:00 -13:00
Location Agnietenkapel

C.A. Drukker, Gene Signature for Risk Stratification and Treatment of Breast Cancer: Incorporating Tumor Biology in Clinical Decision-Making.

Supervisors

Prof. E.J.T. Rutgers
Prof. L.J. van ’t Veer (University of California, San Francisco)

Co-supervisors

Prof. S.C. Linn (UU)
Dr M.K. Schmidt (NKI-AvL)

Agnietenkapel

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.